FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing
Institutions: Ludwig-Maximilians-Universität München, Klinikum St. Marien Amberg, Bayreuth Medical Center, Krankenhaus Nordwest, Klinikum Magdeburg, University Hospital Magdeburg, Klinikum Weiden, Comprehensive Cancer Center Vienna, Medical University of Vienna, Klinikum Chemnitz, Klinikum Stuttgart, Westpfalz Klinikum, Klinikum Leverkusen, Klinikum Darmstadt, Klinikum Fulda, Johannes Gutenberg University Mainz, Jena University Hospital, Pathologisches Institut
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Merck KGaA
OpenAlex ID: W2005348280